FOXM1 and polo-like kinase 1 are co-ordinately overexpressed in patients with gastric adenocarcinomas. (December 2015)

• Record Type: Journal Article
• Authors: Dibb, M.; Han, N.; Choudhury, J.; Hayes, S.; Valentine, H.; West, C.; Sharrocks, AD; Ang, Yeng
• Is Part Of: BMC research notes. Volume 8:Number 1(2015)
• Page Start: 1
• Page End: 9
• Publication Date: 2015-12
• Subjects: Gastric adenocarcinoma -- FOXM1 (Forkhead Protein M1) -- PLK1 (Polo-like Kinase 1); Medicine -- Periodicals; Biology -- Periodicals; 610.5
• DOI: 10.1186/s13104-015-1658-y
• Languages: English
• ISSNs: 1756-0500

Abstract

Abstract Background Gastric cancers present late in life with advanced disease and carry a poor prognosis. Polo-like Kinase 1 (PLK1) is a mitotic kinase with regulatory functions during G2/M and mitosis in the cell cycle. In mammalian cells, there is an intricate co-regulatory relationship between PLK1 and the forkhead transcription factor FOXM1. It has been demonstrated that individually either PLK1 or FOXM1 expression predicts poorer survival. However, the co-expression of both of these markers in gastric adenocarcinomas has not been reported previously. Methods We aimed to assess the expression of PLK1 and FOXM1 in Gastric adenocarcinomas in a Western Population, to examine whether there is a relationship of PLK1 to FOXM1 in cancer samples. We assess both the protein and mRNA expression in this patient population by Tissue Microarray immunohistochemistry and RT-PCR. Results Immunohistochemistry was performed on biopsy samples from 79 patients with gastric cancer. Paired normal controls were available in 47 patients. FOXM1 expression was significantly associated with gastric adenocarcinoma (p = 0.001).PLK1 andFOXM1 co-expression was demonstrated in 6/8 (75 %) tumours when analysed by RT-PCR. FOXM1 is overexpressed in a large proportion of gastric carcinomas at the protein level andFOXM1 andPLK1 are concomitantly overexpressed at the mRNA level in this cancer type. Conclusions This study has demonstrated that FOXM1 and its target genePLK1 are coordinately overexpressed in a proportion of gastric adenocarcinomas. This suggests that chemotherapeutic treatments that target this pathway may be of clinical utility.